Signaling Pathways
Research Area, Signaling Pathways | GlpBio Life Science Products Suppliers
Read More about this categoryShow Less
The antibody-drug conjugate (ADC), a humanized or human monoclonal antibody conjugated with highly cytotoxic small molecules (payloads) through chemical linkers, is a novel therapeutic format and has great potential to make a paradigm shift in cancer chemotherapy. The three components of the ADC together give rise to a powerful oncolytic agent capable of delivering normally intolerable cytotoxins directly to cancer cells, which then internalize and release the cell-destroying drugs. At present, two ADCs, Adcetris and Kadcyla, have received regulatory approval with >40 others in clinical development.
ADCs are administered intravenously in order to prevent the mAb from being destroyed by gastric acids and proteolytic enzymes. The mAb component of the ADC enables it to circulate in the bloodstream until it finds and binds to tumor-specific cell surface antigens present on target cancer cells. Linker chemistry is an important determinant of the safety, specificity, potency and activity of ADCs. Linkers are designed to be stable in the blood stream (to conform to the increased circulation time of mAbs) and labile at the cancer site to allow rapid release of the cytotoxic drug. First generation ADCs made use of early cytotoxins such as the anthracycline, doxorubicin or the anti-metabolite/antifolate agent, methotrexate. Current cytotoxins have far greater potency and can be divided into three main groups: auristatins, maytansines and calicheamicins.
The development of site-specific conjugation methodologies for constructing homogeneous ADCs is an especially promising path to improving ADC design, which will open the way for novel cancer therapeutics.
References:
[1] Tsuchikama K, et al. Protein Cell. 2016 Oct 14. DOI:10.1007/s13238-016-0323-0.
[2] Peters C, et al. Biosci Rep. 2015 Jun 12;35(4). pii: e00225. doi: 10.1042/BSR20150089.
Research Areas
- Proteases(4807)
- Apoptosis(3283)
- Chromatin/Epigenetics(1900)
- Metabolism(3136)
- MAPK Signaling(722)
- Tyrosine Kinase(1585)
- DNA Damage/DNA Repair(2131)
- PI3K/Akt/mTOR Signaling(770)
- Microbiology & Virology(3860)
- Cell Cycle/Checkpoint(1510)
- Ubiquitination/ Proteasome(1381)
- JAK/STAT Signaling(552)
- TGF-β / Smad Signaling(388)
- Angiogenesis(402)
- GPCR/G protein(3686)
- Stem Cell(500)
- Membrane Transporter/Ion Channel(2450)
- Cancer Biology(589)
- Endocrinology and Hormones(999)
- Neuroscience(4307)
- Obesity, Appetite Control & Diabetes(354)
- Peptide Inhibitors and Substrate(1)
- Other Signal Transduction(131)
- Immunology/Inflammation(4778)
- Cardiovascular(821)
- Vitamin D Related(78)
- PROTAC(319)
- Ox Stress Reagents(514)
- Others(4273)
- Antiparasitics(145)
- Toxins(85)
- Drug Derivative(181)
- OGA(1)
- Anti-infection(8)
- Metabolic Enzyme/Protease(21)
Products Related to Signaling Pathways(40122)
- GC808274',4''''-(5'-(4-([2,2':6',2''-Terpyridin]-4'-yl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-diyl)di-2,2':6',2''-terpyridineCAS: 1185464-11-2Purity: >98.00%
4',4''''-(5'-(4-([2,2':6',2''-Terpyridin]-4'-yl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-diyl)di-2,2':6',2''-terpyridine (1,3,5-Tris (4'-tripyridinylphenyl) benzene) is a metal-organic framework (MOF).
- GC808282,2',2'',2'''-(Porphyrin-5,10,15,20-tetrayl)tetrakis(1,3-diethyl-1H-imidazol-3-ium) hexafluorophosphate(V)CAS: 1776118-90-1Purity: >98.00%
2,2',2'',2'''-(Porphyrin-5,10,15,20-tetrayl)tetrakis(1,3-diethyl-1H-imidazol-3-ium) hexafluorophosphate(V) is a metal-organic framework (MOF).
- GC80831UiO-66-(COOH)2CAS: 1458048-15-1Purity: >98.00%
UiO-66-(COOH)2 is a metal-organic framework (MOF).
- GC808331,3,5-Tri(1H-1,2,3-triazol-5-yl)benzeneCAS: 1167993-47-6Purity: >98.00%
1,3,5-Tri (1H-1,2,3-triazol-5-yl) benzene is a tritopic triazole-bridged ligand (H 3 BTTri) that forms a sodalite-type metal-organic framework with coordinatively unsaturated cobalt (II) centers.
- GC80834FITC-Ahx-β-Amyloid (1-42), (rat/mouse) trisPurity: >95.50%
FITC-Ahx-β-Amyloid (1-42), (rat/mouse) (tris) (FITC-Ahx-Amyloid β-peptide (1-42) (rat/mouse) (tris)) is a fluorescently labeled (FITC) form of β-Amyloid (1-42), (rat/mouse), which can be used in Alzheimer's disease-related research, such as aggregation, fiber formation, cellular uptake or imaging experiments.
- GC80835Didesmethyl cariprazine-d 8CAS: 1308279-08-4Purity: >99.00%
Didesmethyl cariprazine -d 8 is the deuterium labeled Didesmethyl cariprazine.
- GC80836rac-LevonordefrinCAS: 6539-57-7Purity: >98.00%
Rac-Levonordefrin (rac-Cobefrin; rac-α-Methylnoradrenaline; rac-Nordefrin) is the racemic form of Levonordefrin.
- GC80837Desmethyl cariprazine-d 8CAS: 1308278-85-4Purity: >99.50%
Desmethyl cariprazine -d 8 is the deuterium labeled Desmethyl cariprazine.
- GC80838Orexin B, human- 13 C 18 , 15 N 3 TFAPurity: >96.50%
Orexin B, human - 13 C 18, 15 N 3 (Human orexin B- 13 C 18, 15 N 3 ) TFA is the 13 C- and 15 N-labeled Orexin B, human.
- GC80839Orexin A- 13 C 18 , 15 N 3 (human, rat, mouse) TFAPurity: >98.50%
Orexin A- 13 C 18, 15 N 3 (human, rat, mouse) ((Hypocretin-1- 13 C 18, 15 N 3 (human, rat, mouse)) TFA is the 13 C- and 15 N-labeled Orexin A (human, rat, mouse).
- GC80840Arecoline-d 5 hydrobromideCAS: 131448-18-5Purity: >98.00%
Arecoline-d 5 hydrobromide is the deuterium labeled Arecoline hydrobromide.
- GC80841Azeliragon-d 9Purity: >98.50%
Azeliragon -d 9 (TTP488-d 9 ) is the deuterium labeled Azeliragon.
- GC80843Acoltremon-d 3Purity: >99.50%
Acoltremon -d 3 (WS-12-d 3 ) is the deuterium labeled Acoltremon.
- GC80844Hydroxylamine- 15 N hydrochlorideCAS: 40711-48-6Purity: >98.00%
Hydroxylamine- 15 N hydrochloride is the 15 N-labeled Hydroxylamine hydrochloride.
- GC80845Spironolactone-d 6 -1Purity: >99.00%
Spironolactone -d 6 -1 is the deuterium labeled Spironolactone.
- GC80846Myristic acid- 13 C 2CAS: 287111-20-0Purity: >98.00%
Myristic acid - 13 C 2 is the 13 C-labeled Myristic acid.
- GC80847(E)-Nerolidol acetateCAS: 85611-33-2Purity: >98.00%
(E)-Nerolidol acetate can be isolated from the oil of Biebersteinia multifida [1] .
- GC808483,4,5-Triiodobenzoic acidCAS: 2338-20-7Purity: >98.00%
3,4,5-Triiodobenzoic acid is an auxin transport inhibitor.
- GC80850Gartisertib-d 8CAS: 1792214-00-6Purity: >98.00%
Gartisertib -d 8 (VX-803-d 8 ) is the deuterium labeled Gartisertib.
| Catalog No. | Product Name | CAS No. | Purity | Structure |
|---|---|---|---|---|
| GC80827 | 4',4''''-(5'-(4-([2,2':6',2''-Terpyridin]-4'-yl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-diyl)di-2,2':6',2''-terpyridine | 1185464-11-2 | >98.00% | |
4',4''''-(5'-(4-([2,2':6',2''-Terpyridin]-4'-yl)phenyl)-[1,1':3',1''-terphenyl]-4,4''-diyl)di-2,2':6',2''-terpyridine (1,3,5-Tris (4'-tripyridinylphenyl) benzene) is a metal-organic framework (MOF). | ||||
| GC80828 | 2,2',2'',2'''-(Porphyrin-5,10,15,20-tetrayl)tetrakis(1,3-diethyl-1H-imidazol-3-ium) hexafluorophosphate(V) | 1776118-90-1 | >98.00% | |
2,2',2'',2'''-(Porphyrin-5,10,15,20-tetrayl)tetrakis(1,3-diethyl-1H-imidazol-3-ium) hexafluorophosphate(V) is a metal-organic framework (MOF). | ||||
| GC80829 | UIO-66-SO3H | 1334722-07-4 | >98.00% | |
UIO-66-SO3H is a metal-organic framework (MOF). | ||||
| GC80830 | MOF-818 | 2254297-29-3 | >98.00% | |
MOF-818 is a metal-organic framework (MOF). | ||||
| GC80831 | UiO-66-(COOH)2 | 1458048-15-1 | >98.00% | |
UiO-66-(COOH)2 is a metal-organic framework (MOF). | ||||
| GC80832 | h-FTAA | 1352477-26-9 | >98.00% | |
h-FTAA is a luminescent conjugated oligothiophene (LCO) probe. | ||||
| GC80833 | 1,3,5-Tri(1H-1,2,3-triazol-5-yl)benzene | 1167993-47-6 | >98.00% | |
1,3,5-Tri (1H-1,2,3-triazol-5-yl) benzene is a tritopic triazole-bridged ligand (H 3 BTTri) that forms a sodalite-type metal-organic framework with coordinatively unsaturated cobalt (II) centers. | ||||
| GC80834 | FITC-Ahx-β-Amyloid (1-42), (rat/mouse) tris | - | >95.50% | |
FITC-Ahx-β-Amyloid (1-42), (rat/mouse) (tris) (FITC-Ahx-Amyloid β-peptide (1-42) (rat/mouse) (tris)) is a fluorescently labeled (FITC) form of β-Amyloid (1-42), (rat/mouse), which can be used in Alzheimer's disease-related research, such as aggregation, fiber formation, cellular uptake or imaging experiments. | ||||
| GC80835 | Didesmethyl cariprazine-d 8 | 1308279-08-4 | >99.00% | |
Didesmethyl cariprazine -d 8 is the deuterium labeled Didesmethyl cariprazine. | ||||
| GC80836 | rac-Levonordefrin | 6539-57-7 | >98.00% | |
Rac-Levonordefrin (rac-Cobefrin; rac-α-Methylnoradrenaline; rac-Nordefrin) is the racemic form of Levonordefrin. | ||||
| GC80837 | Desmethyl cariprazine-d 8 | 1308278-85-4 | >99.50% | |
Desmethyl cariprazine -d 8 is the deuterium labeled Desmethyl cariprazine. | ||||
| GC80838 | Orexin B, human- 13 C 18 , 15 N 3 TFA | - | >96.50% | |
Orexin B, human - 13 C 18, 15 N 3 (Human orexin B- 13 C 18, 15 N 3 ) TFA is the 13 C- and 15 N-labeled Orexin B, human. | ||||
| GC80839 | Orexin A- 13 C 18 , 15 N 3 (human, rat, mouse) TFA | - | >98.50% | |
Orexin A- 13 C 18, 15 N 3 (human, rat, mouse) ((Hypocretin-1- 13 C 18, 15 N 3 (human, rat, mouse)) TFA is the 13 C- and 15 N-labeled Orexin A (human, rat, mouse). | ||||
| GC80840 | Arecoline-d 5 hydrobromide | 131448-18-5 | >98.00% | |
Arecoline-d 5 hydrobromide is the deuterium labeled Arecoline hydrobromide. | ||||
| GC80841 | Azeliragon-d 9 | - | >98.50% | |
Azeliragon -d 9 (TTP488-d 9 ) is the deuterium labeled Azeliragon. | ||||
| GC80842 | (S)-TROX-1 | 2751591-42-9 | >99.50% | |
(S)-TROX-1 is the S-enantiomer of TROX-1. | ||||
| GC80843 | Acoltremon-d 3 | - | >99.50% | |
Acoltremon -d 3 (WS-12-d 3 ) is the deuterium labeled Acoltremon. | ||||
| GC80844 | Hydroxylamine- 15 N hydrochloride | 40711-48-6 | >98.00% | |
Hydroxylamine- 15 N hydrochloride is the 15 N-labeled Hydroxylamine hydrochloride. | ||||
| GC80845 | Spironolactone-d 6 -1 | - | >99.00% | |
Spironolactone -d 6 -1 is the deuterium labeled Spironolactone. | ||||
| GC80846 | Myristic acid- 13 C 2 | 287111-20-0 | >98.00% | |
Myristic acid - 13 C 2 is the 13 C-labeled Myristic acid. | ||||
| GC80847 | (E)-Nerolidol acetate | 85611-33-2 | >98.00% | |
(E)-Nerolidol acetate can be isolated from the oil of Biebersteinia multifida [1] . | ||||
| GC80848 | 3,4,5-Triiodobenzoic acid | 2338-20-7 | >98.00% | |
3,4,5-Triiodobenzoic acid is an auxin transport inhibitor. | ||||
| GC80849 | AtPep1 TFA | - | >98.00% | |
AtPep1 TFA is an endogenous inducer of innate immune responses. | ||||
| GC80850 | Gartisertib-d 8 | 1792214-00-6 | >98.00% | |
Gartisertib -d 8 (VX-803-d 8 ) is the deuterium labeled Gartisertib. | ||||